.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,306,912

« Back to Dashboard

Details for Patent: 6,306,912

Title: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Abstract:Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.
Inventor(s): Mueller; Alan L. (Salt Lake City, UT), VanWagenen; Bradford C. (Salt Lake City, UT), DelMar; Eric G. (Salt Lake City, UT), Balandrin; Manuel F. (Sandy, UT), Moe; Scott T. (Salt Lake City, UT), Artman; Linda D. (Salt Lake City, UT)
Assignee: NPS Pharmaceuticals, Inc. (Salt Lake City, UT)
Filing Date:Jun 07, 1995
Application Number:08/483,294
Claims:1. A compound of the formula ##STR120##

2. A pharmaceutical composition comprising compound 4 ##STR121##

or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

3. Method for treating a patient having a neurological disease or disorder selected from the group consisting of global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, nerve cell damage caused by cardiac arrest or neonatal distress, epilepsy, anxiety, diabetes mellitus, multiple sclerosis, phantom limb pain, causalgia, neuralgias, herpes zoster, spinal cord lesions, hyper algesia, allodynia, Alzheimer's Disease, Huntington's disease, and Parkinson's disease, wherein said treatment comprises administering a pharmaceutical composition comprising compound 4 ##STR122##

or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

4. Method for treating a patient having a neurological disease or disorder selected from the group consisting of global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, nerve cell damage caused by cardiac arrest or neonatal distress, epilepsy, anxiety, diabetes mellitus, multiple sclerosis, phantom limb pain, causalgia, neuralgias, herpes zoster, spinal cord lesions, hyper algesia, allodynia, Alzheimer's Disease, Huntington's disease, and Parkinson's disease, wherein said treatment comprises administering a pharmaceutical composition comprising a compound selected from the group consisting of ##STR123##

or a pharmaceutically acceptable salt thereof.

5. A compound selected from the group consisting of ##STR124##

or a pharmaceutically acceptable salt thereof.

6. A compound selected from the group consisting of ##STR125## ##STR126##

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 6, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising compound 5 ##STR127##

or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

9. Method for treating a patient having a neurological disease or disorder selected from the group consisting of global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, nerve cell damage caused by cardiac arrest or neonatal distress, epilepsy, anxiety, diabetes mellitus, multiple sclerosis, phantom limb pain, causalgia, neuralgias, herpes zoster, spinal cord lesions, hyper algesia, allodynia, Alzheimer's Disease, Huntington's disease, and Parkinson's disease, wherein said treatment comprises administering a pharmaceutical composition comprising ##STR128##

10. Method for treating a patient having a neurological disease or disorder selected from the group consisting of global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, nerve cell damage caused by cardiac arrest or neonatal distress, epilepsy, anxiety, diabetes mellitus, multiple sclerosis, phantom limb pain, causalgia, neuralgias, herpes zoster, spinal cord lesions, hyper algesia, allodynia, Alzheimer's Disease, Huntington's disease, and Parkinson's disease, wherein said treatment comprises administering a pharmaceutical composition comprising a compound selected from the group consisting of ##STR129## ##STR130## ##STR131## ##STR132## ##STR133##

or a pharmaceutically acceptable salt thereof.

11. Method according to claim 4 wherein said compound has an analgesic activity.

12. Method according to claim 4 wherein said compound has a neuroprotectant activity.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc